Clinical findings according to desmosomal genotype
| Pathological genotype (n=6) | Normal genotype (n=41) | p value | |
| Age at presentation (years) | 41 (9) | 42 (11) | 0.96 |
| Sports classification dynamic component | |||
| Class B | 0 | 1 (3%) | 1.0 |
| Class C | 6 (100%) | 39 (97%) | |
| Sports classification static component | |||
| I | 3 (50%) | 8 (20%) | 0.25 |
| II | 0 | 1 (2%) | |
| III | 3 (50%) | 32 (78%) | |
| Level of exercise | |||
| Professional/elite | 2 (33%) | 27 (66%) | 0.31 |
| Amateur competition | 2 (33%) | 7 (17%) | |
| Recreational | 2 (33%) | 7 (17%) | |
| Amount of sport practised | |||
| Years | 22 (9) | 18 (9) | 0.39 |
| Hours per week | 9.2 (2.3) | 14.3 (8.9) | 0.005 |
| Total hours (h/1000) | 10.0 (5.6) | 11.6 (8.6) | 0.69 |
| Family history of ARVC | 1 (17%) | 1 (2%) | 0.24 |
| Presenting symptom | |||
| Aborted sudden death | 2 (33%) | 6 (15%) | 0.49 |
| (Pre)syncope | 4 (67%) | 26 (63%) | |
| Palpitations | 0 | 8 (20%) | |
| Asymptomatic (screening) | 0 | 1 (2%) | |
| Treatment | |||
| ICD (± ablation) | 5 (83%) | 21 (51%) | 0.31 |
| Ablation | 0 | 6 (15%) | |
| Medications | 1 (17%) | 14 (34%) | |
| Follow-up duration (years) | 10 (10) | 7 (5) | 0.34 |
| Outcome | |||
| Major arrhythmic event | 4 (67%) | 11 (28%) | 0.15 |
| (Pre)syncope | 0 | 4 (10%) | |
| Asymptomatic/ Palpitations | 2 (33%) | 25 (62%) | |
| Task force criteria allocation and investigation results | |||
| McKenna Task Force Criteria | |||
| ARVC | 4 (67%) | 20 (50%) | 0.62 |
| Suspected ARVC | 1 (17%) | 15 (37%) | |
| Right Ventricular dysfunction and/ or structural alterations | |||
| Severe RV dysfunction and/or dilation | 2 (33%) | 1 (2%) | 0.04 |
| Localised RV aneurysm | 1 (17%) | 3 (7%) | 0.43 |
| Mild RV dilation or dysfunction | 2 (33%) | 21 (51%) | 0.67 |
| Mild RV segmental dilation | 1 (17%) | 10 (25%) | 1.0 |
| Regional RV hypokinesia | 1 (17%) | 19 (46%) | 0.22 |
| Normal RV morphology and function | 2 (33%) | 15 (37%) | 1.0 |
| RV Ejection Fraction (%) | 32.4 (8.6) | 49.7 (9.4) | 0.006 |
| (in 3 athletes) | (in 24 athletes) | ||
| ECG abnormalities | |||
| Epsilon wave or QRS duration ≥ 110 ms in V1 or V2 | 1 (17%) | 8 (20%) | 1.0 |
| Late potentials | 3 (50%) | 13 (32%) | 0.40 |
| Negative T-waves beyond V2 | 4 (67%) | 14 (34%) | 0.19 |
| Negative T-waves inferior leads | 2 (33%) | 4 (10%) | 0.17 |
| Most severe spontaneous arrhythmia | |||
| SCD/VF | 1 (17%) | 4 (10%) | 0.73 |
| Sustained VT | 4 (66%) | 21 (51%) | |
| Non-sustained VT | 1 (17%) | 13 (32%) | |
| Frequent VEs | 0 | 3 (7%) | |
| Frequent VEs (>1000/24 h) | 3 (50%) | 25 (64%) | 0.66 |
| Inducible Ventricular Arrhythmia | |||
| Sustained VT | 5 (83%) | 18 (46%) | 0.20 |
| Non-sustained VT | 0 | 10 (26%) | |
| Frequent VEs | 1 (17%) | 11 (28%) | |
| Number of VT/VPB morphologies | 1.5 (0.5) | 1.8 (0.8) | 0.36 |
| Dominant VT/VPB morphology | |||
| RVOT | 1 (17%) | 25 (61%) | 0.08 |
| other RV | 5 (83%) | 16 (39%) | |
| Tissue characterisation | |||
| Biopsy performed | 2 | 8 | 1.0 |
| Fibro-fatty replacement | 0 | 0 | |
| Fibrosis alone | 1 (50%) | 2 (25%) | |